CORDIS
EU research results

CORDIS

English EN

Donor T Cells for Immune Control

Objective

Patients with high-risk hematological tumors can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). However, the main causes of failure of HSCT are infections, tumor relapse and over-shooting immune responses of the donor T cells to healthy cells and tissues of the patient or graft-versus host disease (GvHD). Therefore, this treatment is still associated with a high morbidity and mortality, as well as a high economic burden. Our previous EU FP6 project, ALLOSTEM, resulted in a number of achievements, including a ‘first in man’ clinical trial that used a highly innovative novel cell selection strategy (Streptamer technology) for the generation of non-ATMP (advanced therapy medicinal product) monovirus specific T cell products. Continuing from ALLOSTEM, we now aim to develop two novel Streptamer-based clinical cell selection processes and its corresponding cell products. A multispecific T cell product targeting several viruses and tumors as well as a primary regulatory T cell product targeting GvHD will be developed to market maturity. These two cell products will improve the outcome of allogeneic HSCT. A significant improvement in the outcome and this coupled with a significant reduction of the costs for a large number of patients in Europe will further broaden the application in other forms of cancer of this curative treatment. In order to achieve this goal we assembled a consortium led by the University Hospital of Würzburg with Prof. Einsele as scientific coordinator together with renowned clinical scientists in the field of HSCT (all key players in ALLOSTEM).

Coordinator

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Address

Josef-Schneider-Strasse 2
97080 Wurzburg

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 118 101

Administrative Contact

Anne Von Thun (Ms.)

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

ANTHONY NOLAN

United Kingdom

EU Contribution

€ 925 266

JUNO THERAPEUTICS GMBH

Germany

EU Contribution

€ 2 531 268

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 935 110

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 115 766

ARTTIC

France

EU Contribution

€ 57 025

Project information

Grant agreement ID: 601722

Status

Closed project

  • Start date

    1 May 2013

  • End date

    31 January 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 437 856

  • EU contribution

    € 5 682 536

Coordinated by:

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany